Revenue Growth
Total revenue for Q2 2025 was $222.9 million, a 7.6% increase from Q2 2024. Organic revenue grew by 5.4%.
Medical Segment Performance
The Medical segment saw organic revenue growth across all markets, contributing positively to overall performance. Adjusted EBITDA for the Medical segment was $30.1 million, up nearly 20% from last year.
Nuclear Power Market Expansion
Mirion increased its 2025 organic growth expectations for the Nuclear Power sector, citing sizable opportunities across the nuclear landscape, including modernization upgrades and life extensions.
Acquisition of Certrec
Mirion announced the acquisition of Certrec, a leading provider of regulatory compliance solutions to the nuclear industry, which is expected to enhance growth through commercial synergies.
Improved Capital Structure
Mirion completed a $400 million convertible note offering and refinanced a term loan, enhancing financial flexibility and reducing the cost of capital.